c-Yes Inhibitors

SU6656 acts as a selective inhibitor of c-Yes, characterized by its ability to target the enzyme's active site with high specificity. This compound exhibits unique hydrophobic interactions that stabilize its binding, effectively altering the enzyme's conformation. The distinct molecular architecture facilitates a decrease in kinase activity, impacting downstream signaling pathways. Its selective engagement underscores the intricate balance of cellular signaling networks influenced by c-Yes.

Dasatinib inhibits C-yes by binding to its active site, preventing phosphorylation of target substrates and downstream signaling, thus blocking tumor growth.

Herbimycin A functions as a potent modulator of c-Yes, exhibiting a unique ability to disrupt protein-protein interactions essential for its activity. This compound engages in specific hydrogen bonding and hydrophobic contacts, leading to conformational changes that inhibit kinase function. Its distinct structural features allow for selective targeting, influencing various cellular processes and signaling cascades. The compound's kinetic profile reveals a rapid onset of action, highlighting its dynamic role in cellular regulation.

PF 477736 acts as a selective inhibitor of c-Yes, characterized by its ability to interfere with ATP binding through unique molecular interactions. This compound stabilizes a specific conformation of the kinase, effectively blocking its catalytic activity. Its distinct binding affinity alters the enzyme's conformational landscape, impacting downstream signaling pathways. The compound's rapid kinetics facilitate immediate modulation of cellular responses, underscoring its role in fine-tuning kinase activity.

Saracatinib is a dual Src/Abl kinase inhibitor that targets C-yes. It interferes with kinase activity, disrupting cell signaling pathways essential for cancer cell proliferation.

PP2 is a selective C-yes inhibitor that competes with ATP for binding to the kinase domain, blocking tyrosine phosphorylation and downstream signaling.

WH-4-023 inhibits C-yes and other Src family kinases, hindering their kinase activity and downstream signaling, thus suppressing cancer cell proliferation.

PD-166285 inhibits C-yes by blocking ATP binding, resulting in reduced tyrosine phosphorylation and interference with cancer cell growth and metastasis.